AUTHOR=Ricco Anthony , Hanlon Alexandra , Lanciano Rachelle 

TITLE=Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database

JOURNAL=Frontiers in Oncology

VOLUME=Volume 7 - 2017

YEAR=2017

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00185

DOI=10.3389/fonc.2017.00185

ISSN=2234-943X

ABSTRACT=PURPOSE: No direct comparisons between extreme hypofractionation and conventional fractionation have been reported in randomized trials for the treatment of localized prostate cancer. The goal of this study is to use a propensity score matched (PSM) analysis with the National Cancer Database (NCDB) for the comparison of stereotactic body radiation therapy (SBRT) and intensity modulated radiation therapy (IMRT) for organ confined prostate cancer.

METHODS: Men with localized prostate cancer treated with radiation dose greater than 72Gy for IMRT and 35Gy for SBRT to the prostate only were abstracted from the NCDB. Men treated with previous surgery, brachytherapy, or proton therapy were excluded. Matching was performed to eliminate confounding variables via PSM. Simple 1-1 nearest neighbor matching resulted in a matched sample of 5,430 (2715 in each group). Subset analyses of men with PSA>10, GS=7, and GS >7 yielded matched samples of 1020, 2194, and 247 respectively.

RESULTS: No difference in survival was noted between IMRT and SBRT at 8 years (p=0.65).  Subset analyses of higher risk men with PSA>10 or GS=7 histology or GS>7 histology revealed no difference in survival between IMRT and SBRT (p=0.58, p=0.68 and 0.62 respectively).   Variables significant for survival for the matched group included: age (p<0.0001), primary payor (p=0.0001), Charlson/Deyo Score (p=0.0002), PSA (p=0.0013), Gleason score (p<0.0001) and use of hormone therapy (p=0.02).

CONCLUSIONS: Utilizing the NCDB, there is no difference in survival at 8 years comparing IMRT to SBRT in the treatment of localized prostate cancer.  Subset analysis confirmed no difference in survival even for intermediate and high risk patients based on Gleason Score and PSA.